Stockreport

Cytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF Data Supports Inclusion of Japan in GALACTIC-HF Company is Eligible to Earn $10 Million Milestone Payment from Amgen upon First Patient Dosing in Japan in Phase 3 Outc [Read more]